Gyre Therapeutics Ownership | Who Owns Gyre Therapeutics?


OverviewRevenueFinancialsChart

Gyre Therapeutics Ownership Summary


Gyre Therapeutics is owned by 1.59% institutional investors, 87.10% insiders, and 11.31% retail investors. Vanguard group is the largest institutional shareholder, holding 1.35% of GYRE shares.

GYRE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockGyre Therapeutics1.59%87.10%11.31%
SectorHealthcare Stocks 232.51%10.72%-143.23%
IndustryBiotech Stocks 384.56%10.58%-295.14%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group1.20M1.35%$8.48M
Blackrock funding, inc. /de720.29K0.81%$5.09M
Geode capital management423.22K0.47%$2.99M
State street182.75K0.21%$1.36M
Sbi securities162.91K0.18%$1.15M
Charles schwab investment management123.39K0.14%$920.46K
Northern trust116.34K0.13%$867.91K
Morgan stanley54.50K0.06%$384.76K
Bank of new york mellon41.20K0.05%$290.89K
State of wisconsin investment board39.00K0.04%$290.94K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sbi securities162.91K0.03%$1.15M
State of wisconsin investment board39.00K0.00%$290.94K
Activest wealth management533.000.00%$3.76K
Tower research capital llc (trc)2.69K0.00%$20.10K
Strs ohio21.10K0.00%$148.97K
State of alaska, department of revenue5.22K0.00%$36.00K
Geode capital management423.22K0.00%$2.99M
Northern trust116.34K0.00%$867.91K
Rhumbline advisers13.43K0.00%$100.20K
Mirae asset global etfs4.20K0.00%$31.35K

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de720.29K0.00%60.89K
Vanguard group1.20M0.00%51.03K
Geode capital management423.22K0.00%48.60K
Morgan stanley54.50K-45.52K
Bank of new york mellon41.20K0.00%16.80K

Top Sellers

HolderShares% AssetsChange
Northern trust116.34K0.00%-26.99K
Nuveen---17.59K
Advantage alpha capital partners lp---13.66K
Ubs group9.58K--13.38K
Verition fund management---13.35K

New Positions

HolderShares% AssetsChangeValue
Dimensional fund advisors lp10.90K-10.90K$76.97K
Russell investments group1.12K-1.12K$8.38K
Optiver b.v.222.00-222.00$1.66K

Sold Out

HolderChange
True wealth design-6.00
Us bancorp \de\-17.00
Rise advisors-54.00
Srs capital advisors-57.00
Federation des caisses desjardins du quebec-75.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202510-78.26%1,417,139-54.22%113.18%3-87.50%3-78.57%
Sep 30, 202515-65.12%1,514,519-54.84%112.00%6-80.65%5-28.57%
Jun 30, 2025464.55%3,409,78030.67%341.97%3447.83%7-50.00%
Mar 31, 20254415.79%2,609,38057.10%380.28%2315.00%1455.56%
Dec 31, 20243911.43%1,787,60711.02%259.05%21-4.55%950.00%

Recent Insider Transactions


DateNameRoleActivityValue
May 28, 2025Ma Songjiang PresidentSell$5.62K
May 27, 2025Ma Songjiang PresidentSell$20.56K
May 23, 2025Ma Songjiang PresidentSell$1.86K
May 22, 2025Ma Songjiang PresidentSell$21.94K
May 20, 2025Ma Songjiang PresidentSell$22.50K

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q3--
2025 Q2-12
2025 Q1-59
2024 Q4-14

GYRE Ownership FAQ


Who Owns Gyre Therapeutics?

Gyre Therapeutics shareholders are primarily institutional investors at 1.59%, followed by 87.10% insiders and 11.31% retail investors. The average institutional ownership in Gyre Therapeutics's industry, Biotech Stocks , is 384.56%, which Gyre Therapeutics falls below.

Who owns the most shares of Gyre Therapeutics?

Gyre Therapeutics’s largest shareholders are Vanguard group (1.2M shares, 1.35%), Blackrock funding, inc. /de (720.29K shares, 0.81%), and Geode capital management (423.22K shares, 0.47%). Together, they hold 2.63% of Gyre Therapeutics’s total shares outstanding.

Does Blackrock own Gyre Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Gyre Therapeutics.

Who is Gyre Therapeutics’s biggest shareholder by percentage of total assets invested?

Sbi securities is Gyre Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.03% of its assets in 162.92K Gyre Therapeutics shares, valued at 1.15M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools